Ixtlan

Sinobiomed's Good News Raises Suspicion

your comments are much appreciated although the wanferon/wanferin treatments for hepatitis have huge competition....the malaria drug and rBat are a ways off from approval, providing they make it thru phase IIb and onto phase III...

true that the land is worth significantly more than what its carried on the books at but in pudong, you still have to apply for a redevelopment license and then have to wait until the company finds another GMP approved site to relocate to in the event the land is sold.....that could take up to two years....

looks a bit 'promoterish' so you might consider tempering your enthusiasm with some reality checks - for one, 2009 will not be an earnings positive year even if the company merges with or acquires another company....not a big deal but saying its going to $11 is a bit far fetched....

lets watch the news flow and see how they are going to restructure the company and then evaluate potential.

Sinobiomed's Good News Raises Suspicion

500k is indeed a relatively small amount....however, there could be warrants attached for a larger aggregate amount..

additionally, professional relationships that accelera has might very well extend into the life science field both in china and in the u.s....

further, it would be possible that this is the first step of several that could put the company in an 'interesting' position - there are a handful of larger, listed companies that trade in the u.s. that produce and distribute generic drugs and partnering with a company that has some novel drugs in the pipeline is a great way to expand future growth drivers....this could include strategic investment, strategic partnership and/or m&a...

you make a very good point about the SFDA and the myriad ways in which they work...let's hope that sinobiomed is in the know and able to successfully navigate thru the balance of the clinical trials.